U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07249788) titled 'Resmiterom Efficacy & Safety in Patients With MASH' on Nov. 18.
Brief Summary: Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.
Study Start Date: Nov. 30
Study Type: INTERVENTIONAL
Condition:
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Intervention:
DRUG: Resmetirom
1st FDA approved MASH therapy
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Nabiqasim Industries (Pvt) Ltd
Information provided by (Responsible Party): Dr Hussain Abidi, Nabiqasim Industries (Pvt) Ltd
Disclaimer: Curated by HT Syndication....